Page last updated: 2024-10-23

bevantolol and Chorea

bevantolol has been researched along with Chorea in 1 studies

bevantolol: structure given in first source
bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.

Chorea: Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Gamez, J2
Calopa, M2
Muñoz, E2
Ferré, A2
Huertas, O2
McAllister, K2
Reig, N2
Scart-Grès, C2
Insa, R2
Kulisevsky, J2

Trials

1 trial available for bevantolol and Chorea

ArticleYear
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:5

    Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular

2023
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:5

    Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular

2023
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:5

    Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular

2023
A proof-of-concept study with SOM3355 (bevantolol hydrochloride) for reducing chorea in Huntington's disease.
    British journal of clinical pharmacology, 2023, Volume: 89, Issue:5

    Topics: Chorea; Double-Blind Method; Humans; Huntington Disease; Tetrabenazine; Treatment Outcome; Vesicular

2023